Synergy between technologies speeds up drug optimization cycle
Cambridge, UK – 7th June 2016 – Cresset, innovative provider of software and contract research services for small molecule discovery and design, is pleased to announce the release of the new Spark reagent databases based on available compounds from eMolecules. This will enable researchers to use Spark to find the best R-groups for their projects, whilst also enabling a close link between Spark’s suggestions and the chemistry they want to use, based on reagents they can easily procure.
“Spark is a leading bioisostere replacement tool,” explains Dr Robert Scoffin, CEO of Cresset. “It uses the electrostatic and steric properties of molecules to suggest the best replacements to help you to explore R-groups, hop scaffolds and grow and link fragments. We already have a diverse range of practical fragment and reagent databases, plus the possibility to create your own from in-house compound libraries. The addition of the Spark eMolecules reagent databases will provide Spark users with over 500,000 reagents that are easy to order with known availability. This represents an exciting and powerful new way of generating novel, diverse structures for their projects, linking bioisosteric replacement ideas to chemical feasibility.”
“eMolecules catalogues over 6 million unique chemical structures from vendors worldwide, translating into 1.5 million building blocks,” explains Niko Gubernator, CEO at eMolecules. “Spark from Cresset offers market leading bioisosteric replacement capability and we are delighted that Spark users are now able to use eMolecules to link their results to commercially available compounds. This innovation will speed up the drug optimization cycle, empowering chemists to make the best synthetic choices for their project.”
- Cresset: Sue Peffer, Marketing Manager, firstname.lastname@example.org, +44 (0)1223 858890
- eMolecules: Lester Marrison, VP Business Development, Europe and Asia, email@example.com, +44 1438791108 / +44 7711030983
Cresset’s software and contract research services are used by chemists from the world’s leading research organizations. Our patented methods deliver novel, realistic results for discovering, designing and optimizing the best small molecules in industry sectors including: agrochemicals, fine chemicals, flavor, fragrance and pharmaceuticals. For more information visit www.cresset-group.com
eMolecules is driven to remove the fear, hurt and heartbreak of health problems worldwide, by enabling scientists to accelerate their research to find the cures. To achieve this eMolecules provides business intelligence data and integrated ecommerce software for screening compound, chemical building blocks and primary antibody supply chains. These tools combined with their acquisition, aggregation and analytical services greatly empower drug discovery researchers working in the pharmaceutical, biotechnology, academia, CRO and agrochemical industries. A privately owned company, eMolecules was founded in 2005 at its San Diego headquarters and has offices in Boston and London employing over 40 people across the three sites. For more information visit https://www.emolecules.com/.